Charlie's Holdings FY22 Revenue Grows 23% To $26.4M, Here Is What You Need To Know

Zinger Key Points
  • Gross profit was $10.0 million, a decrease of 10%, compared with $11.1 million for the year ended December 31, 2021.
  • Gross margin was 37.8%, compared with 51.5% for the year ended December 31, 2021.

Charlie's Holdings, Inc. CHUC revenue for the year ended December 31, 2022, was $26.4 million, an increase of 23%, compared with $21.5 million for the year ended December 31, 2021. The increase in revenue was primarily due to a $4.0 million increase in Charlie's nicotine-based product sales, and a $900,000 increase in sales of the company's hemp-derived products.

FY 2022 Financial Highlights

  • Gross profit was $10.0 million, a decrease of $1.1 million, or 10%, compared with $11.1 million for the year ended December 31, 2021.

  • Gross margin was 37.8%, compared with 51.5% for the year ended December 31, 2021.

  • Operating loss was $1.8 million compared to operating income of $600,000 in 2021.

  • Including the fair value of derivative liabilities, net loss was $1.6 million compared to net income of $4.8 million in 2021.

"2022 was a very strong year for Charlie's, as we continued our growth trajectory by increasing revenue to an all-time Company record of $26.4 million," stated Matt Montesano, Charlie's Holdings, CFO. "Despite increasing investment in our future, by filing new PMTAs for our synthetic nicotine Pacha products, investing in "age-gating technology" research and development, and investing in the development of new alternative alkaloid vapor products, we improved operating efficiency as our operating expenses, as a percentage of revenue, declined from 49% to 45% for the full year 2022."

Henry Sicignano III, Charlie's president, stated, "Our team has developed - and begun executing - a well laid-out strategic plan with focus on three broad initiatives: development of proprietary technology and novel new products, expansion of the company's hemp-derived alternative cannabis product line and focus on top line growth. Through the course of 2023, we will continue to concentrate our resources on areas of our business in which we enjoy competitive advantages in order to increase market share, sales, and, ultimately, Charlie's marketcap. I am proud to report: Charlie's is extremely well positioned to enjoy very substantial growth over the next 12-18 months."

Photo by Giorgio Trovato on Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsPenny StocksMarketsHenry Sicignano IIIMatt Montesanopremium
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.